China's CStone Pharmaceuticals H1 revenue soars on drug sales

CStone Pharmaceuticals

27/08/2026 12:40

Overview
China biopharma firm's half-year revenue rose 315% yr/yr to RMB205.1 mln
Revenue growth driven by higher pharmaceutical sales, especially pralsetinib after NRDL inclusion
Loss for the period narrowed, while R&D expenses rose due to increased clinical trial costs

Outlook
CStone plans to initiate global Phase III trials for CS2009 by end of 2026
Company expects additional CS2009 registration studies in 2027 and following years

Result Drivers
NRDL INCLUSION - Revenue growth was primarily driven by increased sales of pharmaceutical products, especially pralsetinib, after its inclusion in the National Reimbursement Drug List
CLINICAL TRIAL COSTS - R&D expenses rose due to increased third-party contracting costs for clinical trials, including the Phase II study for CS2009 and other research programs

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
H1 Revenue
 
RMB 205.1 mln
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy"
Wall Street's median 12-month price target for CStone Pharmaceuticals is HK$16.90, about 165.3% above its August 27 closing price of HK$6.37
The stock recently traded at 12 times the next 12-month earnings vs. a P/E of 43 three months ago

Reuters Recommended Reads
Aug 25 - China's Innovent Biologics H1 revenue, profit rise on strong product sales
Aug 26 - China's Hansoh Pharma posts 36% rise in first-half profit helped by innovative drug sales
Aug 27 - Biocytogen Pharmaceuticals H1 revenue up 51.6%

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)